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Abstract
Introduction The purpose of this review was to evaluate the
impact of corticosteroids on the outcomes of patients with
severe community-acquired pneumonia (CAP).
Methods We performed a systematic MEDLINE, Cochrane
database, and CINAHL search (1966 to November 2007) to
identify full-text publications that evaluated the use of
corticosteroids in CAP.
Results An initial literature search yielded 109 articles, and 105
studies were excluded after the first analysis. We found four
studies eligible for analysis. On the basis of their results, the use
of corticosteroids as adjunctive therapy in severe CAP should
be categorized as a weak recommendation (two studies) and a
strong recommendation (two studies) with either low- or
moderate-quality evidence. However, no evidence of adverse
outcomes or harm is present in the evaluated studies.
Conclusion According to the GRADE system, available studies
do not support the recommendation of corticosteroids as a
standard of care for patients with severe CAP. Further
randomized controlled trials with this aim should enroll a larger
number of severely ill patients. However, in patients needing
corticosteroids, it may be reasonable to conclude that
corticosteroid administration is safe in patients with severe
infections receiving antimicrobial therapy.
Introduction
Community-acquired pneumonia (CAP) is associated with sig-
nificant morbidity and mortality and is the most common cause
of death from infectious diseases in developed countries [1].
Patients with severe CAP often require intensive care unit
admission and mechanical ventilation. An exceedingly high
mortality rate is observed in these patients despite significant
advances in etiological investigation, antimicrobial therapy,
and improvements in supportive care [2]. With perhaps a few
exceptions [3,4], adjunctive therapies for severe infections
have failed to fulfill their promise in the past years [5].
Nevertheless, with the concept of critical illness-related corti-
costeroid insufficiency (CIRCI) and the results of clinical trials
showing respiratory [6,7], immune [8,9], and hemodynamic [7]
benefits, corticosteroids have re-emerged as promising
adjuncts for the treatment of severe sepsis [10]. In the past
years, several studies evaluated the pulmonary [11] and sys-
temic [12] inflammatory response as well as data on the adre-
nal function [13,14] of patients with severe CAP. In addition,
the administration of systemic corticosteroids is associated
with reduced pulmonary inflammation in patients with bacterial
pneumonia [11] and acute lung injury [15] and improved oxy-
genation and outcomes in patients with Pneumocystis jirovecii
pneumonia [16]. Recent guidelines for the management of
CAP suggest the benefit of systemic corticosteroids for
patients with a severe presentation [1]. Yet at the time of their
publication, only data from a single small randomized control-
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led trial (RCT) demonstrating improved survival were available
[6]. At present, few studies have addressed the use of corti-
costeroids in the treatment of patients with CAP and their role
is still unclear in this setting. In the present article, we reviewed
recent peer-reviewed reports to determine whether systemic
corticosteroids have an impact on the outcomes of patients
with severe CAP. In addition, we explored possible explana-
tions for the observed results.
Materials and methods
Selection of participants, data collection, and definitions
We performed a systematic search of MEDLINE, the
Cochrane database, and CINAHL (for the period of 1966 to
November 2007) to identify full-text English language publica-
tions that evaluated the use of corticosteroids in CAP. Inclu-
sion criteria were established a priori. Major MeSH (Medical
Subject Heading) search terms included 'community-acquired
infections', 'pneumonia', 'steroids', 'corticosteroids', 'glucocor-
ticoids', and 'cortisol'. We also reviewed the references of
available studies for other potentially eligible studies, and addi-
tional published reports were identified through a manual
search of citations from retrieved articles. Only original peer-
reviewed clinical trials and cohort studies evaluating the use of
corticosteroids in patients with severe CAP were selected and
analyzed. The abstracts of all articles were used to confirm our
target population (patients with CAP), and the corresponding
full-text articles were reviewed for the presence of data evalu-
ating the outcomes of adult non-immunocompromised
patients with severe CAP treated with systemic corticoster-
oids. Only studies of at least 20 adult patients were included.
We excluded case reports, articles in which children were the
subject of study, articles on CAP in HIV-infected patients,
nosocomial pneumonia, or CAP managed in an outpatient set-
ting. Two investigators (JIFS and PP) independently identified
the eligible literature. Predefined variables were collected,
including year of publication, study design (prospective/retro-
spective), number of patients included, and hospital mortality
and length of stay (LOS), oxygenation, markers of systemic
inflammation, and data on pneumonia severity. Additional
unpublished data were obtained by electronic mail from Gar-
cia-Vidal and Mikami. Any inconsistencies between the two
investigators (JIFS and PP) in interpretation of data were
resolved by consensus. The data were extracted to a stand-
ardized form and included the number of patients, hospital
mortality and LOS, oxygenation, markers of systemic inflamma-
tion, and data on pneumonia severity. In addition, we explored
possible reasons that may explain the results and assigned
quality levels as defined by the American Thoracic Society
(ATS) GRADE system to formulate the level of recommenda-
tion [17].
Results
The initial literature search yielded 109 articles. One hundred
four studies were excluded based on their titles and abstracts.
One article was excluded after revision for involving both
patients with CAP and hospital-acquired pneumonia [18]. The
complete flow diagram and reasons for exclusion are pre-
sented in Figure 1. Eventually, we selected four studies that
evaluated the use of corticosteroids for severe CAP. These
studies are summarized in Tables 1 and 2.
Two studies found a significant reduction in mortality for
patients with severe CAP treated with corticosteroids [6,19].
The study of Confalonieri and colleagues [6], a small-sized (n
= 46) multicenter RCT, showed an impressive reduction in
hospital mortality (30% versus 0%; P = 0.009) with a 7-day
continuous infusion of hydrocortisone (240 mg/day). Garcia-
Vidal and colleagues [19] evaluated 308 patients in a large
retrospective single-center cohort study and demonstrated in
a multivariate analysis that the use of corticosteroids was
strongly associated with a lower mortality (hospital mortality;
odds ratio, 0.287; 95% confidence interval, 0.113 to 0.732).
These patients were treated with a median dose of 45 mg/day
of methylprednisolone for a mean period of 11.4 days. In a
small open-label RCT evaluating 31 patients hospitalized for
CAP, no mortality benefit was observed in patients receiving a
3-day course of 40 mg of prednisolone as compared with pla-
cebo [20]. Marik and colleagues [21] evaluated the effects on
clinical course of a single dose of hydrocortisone administered
to patients (n = 30) with severe CAP 30 minutes before anti-
biotic therapy. In this small RCT, no improvement in survival
was observed.
Regarding the LOS, two studies found a reduction in LOS for
patients treated with corticosteroids [6,19] which could not be
demonstrated in the remaining studies [20,21]. The role of
CIRCI was not systematically addressed in any of the studies.
Only the study of Mikami and colleagues [20] evaluated the
adrenal function of patients with CAP. In a subset of patients
(23/31), total cortisol levels at baseline and after ACTH
(adrenocorticotropic hormone) stimulation were measured
showing a 43% prevalence of CIRCI. Only the study by Con-
falonieri and colleagues [6] provides detailed data on the pres-
ence of acute lung injury and septic shock, only. In the study
by Confalonieri and colleagues [6], 34 (79%) of all patients
had arterial partial pressure of oxygen/fraction of inspired oxy-
gen (PaO2/FiO2) ratios of less than 200 mm Hg and most of
them were in the placebo arm of the study (21 [91%] versus
13 [57%]; P = 0.01). Regarding the presence of shock at
baseline, Confalonieri and colleagues [6] reported a low over-
all rate of vasopressor dependency (n = 3 [7%]).
Possible side effects of using corticosteroids, such as
increased risk of nosocomial infections, myopathy, and hyper-
glycemia, were not systematically investigated and are not
reported by most studies [19-21]. However, no increased hos-
pital LOS or mortality was observed. Moreover, Confalonieri
and colleagues [6] prospectively evaluated all patients
enrolled in the study for the occurrence of such complications
and could not demonstrate an increased risk of such compli-Available online http://ccforum.com/content/12/3/R76
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cations in patients using hydrocortisone as compared with
placebo.
Design and patient selection
Three studies were designed as a prospective RCT [6,20,21]
and only one study evaluated a retrospective cohort [19].
Selection criteria were variable in the four studies. Confalonieri
and colleagues [6] used the modified ATS criteria for severe
CAP [22], and Marik and colleagues [21] applied the British
Thoracic Society criteria for severe CAP [23]; both studies
included a homogenous group of patients with severe CAP.
Garcia-Vidal and colleagues [19] retrospectively evaluated
only patients with severe CAP (classes IV and V of the pneu-
monia severity index [PSI] score) [24], and data were acquired
from the medical charts. Despite the retrospective design,
strict inclusion criteria were applied in this study. The study by
Mikami and colleagues [20] evaluated patients with a wide
spectrum of severity (from classes I to V) that required hospi-
talization due to CAP, and 55% of the patients were catego-
rized as classes IV and V of the PSI score. However, most
patients had significant disease severity at presentation as
hypoxemia (mean PaO2 on presentation = 61 ± 8 mm Hg) and
respiratory distress (mean respiratory rate = 29 ± 8 breaths
per minute).
Validation of available studies
We assigned evidence levels to the reviewed studies based
on the GRADE system definitions adopted by ATS [17].
Figure 1
Flow diagram of selection of studies Flow diagram of selection of studies. CAP, community-acquired pneumonia.
Table 1
Clinical studies on the role of corticosteroids in severe community-acquired pneumonia
Reference Study design Sample size, 
number
Patient selection Corticosteroids 
(drug/regimen)
Primary endpoints Level of evidence 
and 
recommendation
Marik, et al. [21] Single-center RCT 30 Severe CAP Hydrocortisone 10 
mg/kg versus 
placebo 30 minutes 
before antibiotics
Mortality, clinical 
course, and serum 
TNF-α levels
Weak 
recommendation, 
moderate-quality 
evidence
Confalonieri, et al. [6] Multicenter RCT 46 Severe CAP Hydrocortisone 200 
mg + 
hydrocortisone 10 
mg/hour for 7 days 
versus placebo
Mortality, clinical 
course, and 
systemic 
inflammation
Strong 
recommendation, 
moderate-quality 
evidence
Mikami, et al. [20] Open-label RCT 31 Moderate and 
severe CAP
Prednisolone 40 mg 
qd for 3 days versus 
placebo
Mortality and 
clinical course
Weak 
recommendation, 
low-quality 
evidence
Garcia-Vidal, et al. [19] Retrospective 
cohort study
308 Severe CAP Methylprednisolone 
14.5 mg (or 
equivalent) qd for 
11.4 days
Mortality Strong 
recommendation, 
low-quality 
evidence
CAP, community-acquired pneumonia; qd, quaque die (every day); RCT, randomized controlled trial; TNF-α, tumor necrosis factor-alpha.Critical Care    Vol 12 No 3    Salluh et al.
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Based on these evidence levels, a graded recommendation
can be formulated for the use of corticosteroids in severe
CAP. Three of the studies were prospective RCT and one was
a retrospective cohort study and, as a result, classified low-
quality evidence [20], moderate-quality evidence [6], moder-
ate-quality evidence [21], and low-quality evidence [19] as a
weak recommendation, a strong recommendation, a weak rec-
ommendation, and a strong recommendation, respectively.
Therefore, according to the ATS GRADE system, the use of
corticosteroids in severe CAP should be graded as a weak
recommendation [17].
Discussion
Patient selection bias
Selection bias usually is implicated as a plausible explanation
for the results observed in clinical trials involving a small
patient population. In the present case, the lack of survival ben-
efit observed in the study of Mikami and colleagues [20] may
be ascribed to the enrollment of patients with a lower degree
of severity in the study (45% of the patients had PSI scores of
II or less). However, even though mortality benefits were not
observed (and the study was clearly underpowered for mortal-
ity), improvements in clinical condition were more frequent in
patients treated with corticosteroids.
Nonetheless, the opposite may also be considered. Positive
results found by trials with a small number of patients may hap-
pen due to either selection bias or chance. In the study by
Confalonieri and colleagues [6], a large number of the patients
were assessed for eligibility but did not meet the inclusion cri-
teria (69/121, 57%). Moreover, despite the long duration of
the inclusion period (3 years) in six centers, only 46 patients
were included in the study's final analysis. Also, the number of
patients requiring invasive mechanical ventilation (16/23,
70%) in the placebo group was substantially higher than in the
hydrocortisone group (7/23, 30%; P value = 0.008). Such dif-
ferences in patient selection may have affected outcomes.
Safety issues
Several patients admitted to the hospital experience infection-
related exacerbations of asthma or chronic obstructive pulmo-
nary disease (COPD) which are severe enough to require the
use of systemic corticosteroids for a few days [19,25]. This
usually poses a significant dilemma as clinicians caring for
these patients often fear that the use of corticosteroids may
adversely affect the immune response and, in doing so, com-
promise the resolution of the infection. While the evaluated
studies have not clearly addressed safety issues in a system-
atic way, at least two studies reported no significant adverse
events related to the use of corticosteroids [6,20]. Moreover,
in the study by Garcia-Vidal and colleagues [19], a signifi-
cantly higher number of patients treated with corticosteroids
had COPD and their survival rates were superior to those of
patients not receiving corticosteroids. The remaining studies
[20,21] failed to show increased morbidity or mortality in
patients receiving systemic corticosteroids. Therefore, despite
the fact that this was not a primary endpoint in any of these
studies, it seems that corticosteroid administration is safe in
patients receiving antimicrobial therapy.
Possible explanations for the reported outcomes
Duration of corticosteroid therapy
Several studies demonstrated that a short-course high-dose
corticosteroid regimen is not associated with any survival ben-
efit and could even be deleterious [26]. In contrast, lower
doses for longer periods have been associated with improved
survival and earlier shock reversal [7]. The four evaluated
studies could be divided according to the duration of corticos-
teroid therapy in short and long courses. Two studies can be
classified as short-course: in the study by Marik and col-
leagues [21], corticosteroids were given as a single dose, and
Table 2
Effects of corticosteroids versus placebo on different endpoints of severe community-acquired pneumonia studies
Reference Mortality, percentage Clinical course Systemic 
inflammation
LOS, days MODS AB duration, days
Marik, et al. [21] 7.1 versus 18.8 
(P = NS)
4.6 versus 4.3 N/A N/A Plasma TNF-α 
concentrations; no 
effect
Confalonieri, et al. [6] 0 versus 30 
(P = 0.009)
10 versus 18 
(P = 0.01)
0.3 versus 1.0 
(P = 0.003)
N/A Lower CRP levels at 
day 8 18 versus 34 
mg/dL (P = 0.01)
Mikami, et al. [20] 6 versus 0 (P = 0.99) 11.3 versus 15.5 
(P = 0.182)
N/A 8.5 versus 12.3 
(P = 0.026)
CRP Faster 
normalization of CRP 
levels (7.6 versus 
11.7 days; P = 0.02)
Garcia-Vidal, et al. [19] OR, 0.287; 95% CI, 
0.113 to 0.732
7.1 versus 13.8 
(P = 0.005)
N/A N/A N/A
AB, antibiotic therapy; CI, confidence interval; CRP, C-reactive protein; LOS, length of stay; MODS, multiple organ dysfunction score; N/A, not 
available; NS, not significant; OR, odds ratio; TNF-α, tumor necrosis factor-alpha.Available online http://ccforum.com/content/12/3/R76
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in the study by Mikami and colleagues [20], they were given
once daily for 3 days. In contrast, in the RCT conducted by
Confalonieri and colleagues [6], corticosteroids were given by
continuous infusion for 7 days, and in the retrospective study
of Garcia-Vidal and colleagues [19], they were given (on aver-
age) during 11.4 days. A detailed analysis of the results from
the four studies demonstrated that those in which corticoster-
oids were given in a short course showed no benefits concern-
ing the primary endpoints. Conversely, in the studies with
longer corticosteroid courses, a significant benefit in mortality
and in other clinical variables was registered (Table 2). How-
ever, the results from the CORTICUS (Corticosteroid Therapy
of Septic Shock) trial [27] showed no survival benefit with a
relatively long corticosteroid course (11 days) and challenged
this observation. Consequently, the optimum duration of corti-
costeroid therapy remains controversial.
The role of critical illness-related corticosteroid insufficiency
Recent ATS/Infectious Diseases Society of America guide-
lines [1] state that hypotensive fluid-resuscitated patients with
severe CAP should be screened for occult CIRCI (level II evi-
dence). However, among the evaluated studies, only that of
Mikami and colleagues [20] analyzed the adrenal function in a
subset of patients. While the authors stated that 43% of
patients fulfilled criteria for CIRCI, further data on these
patients were not reported in the paper. A significant preva-
lence of CIRCI was described in recent studies [13,14].
Accordingly, Annane and colleagues [28] recently evaluated
patients with septic shock (60% of them pneumonia-related)
and showed that low doses of corticosteroids were associ-
ated with better outcomes in sepsis-associated acute respira-
tory distress syndrome diagnosed with CIRCI. Therefore, the
treatment of undiagnosed underlying CIRCI could have played
a role in the improvement of corticosteroid-treated patients.
However, recent data suggest that the corticotropin test is
unable to identify patients who may respond to steroid therapy
[10,27]. For this reason, the usefulness of measuring the adre-
nal function in patients with severe sepsis remains a conten-
tious issue.
Hemodynamic effects of corticosteroids
Currently, the differentiation between severe sepsis and septic
shock is made on the basis of vasopressor dependency in the
latter group. The results of clinical trials on the use of steroids
in septic patients are variable regarding immunomodulation,
reversal of organ failures, and impact on the survival rates [7-
9,27,29]. In contrast, the effect of hydrocortisone in reducing
the need for vasopressors is indisputable [30]. Increase in the
mean arterial blood pressure in response to steroids is associ-
ated with an increase in systemic resistance and a reduction
in cardiac index and heart rate since corticosteroids have a
role in regulating the peripheral vascular tone. Such an effect
is explained by the inhibition of nitric oxide as well as the
increase in the expression of catecholamine receptors. Confal-
onieri and colleagues [6] report a reduced frequency of
'delayed septic shock' in patients treated with hydrocortisone.
Mikami and colleagues [20] also demonstrated a faster stabi-
lization of vital signs in patients treated with corticosteroids but
data on mean arterial pressure or lactate levels are not availa-
ble. Garcia-Vidal and colleagues [19] observed that patients
with severe CAP on corticosteroid therapy and equal Charlson
score, PSI class, and hypotension at admission do better than
those without corticosteroid therapy. However, no further
details on clinical data improvement are provided in the article.
Hemodynamic benefits associated with steroid therapy could
play a significant role in precluding hypoperfusion and multi-
organ failure from thus having an impact on mortality.
Immunomodulatory effects of corticosteroids
Cytokines and mediators of inflammatory response play a key
role in the pathogenesis of severe infections and sepsis-
related organ failure and prognosis [31-33]. Several studies
demonstrated that the infusion of moderate doses of corticos-
teroids could blunt the systemic pro-inflammatory cytokine
response in severe sepsis [8,9] and the pulmonary inflamma-
tion in severe pneumonia [11] and acute lung injury [15]. How-
ever, Marik and colleagues [21] were unable to observe any
difference in tumor necrosis factor-α course between patients
treated with and without hydrocortisone. However, we could
speculate that at least part of the clinical improvement
observed may be ascribed to the immunomodulatory effects of
the steroid infusion, thus hastening the resolution of acute lung
injury and organ failures. Of the four studies, two evaluated the
effect of corticosteroids on surrogate biomarkers of systemic
inflammation and observed more significant reductions in C-
reactive protein (CRP) levels in patients treated with corticos-
teroids [6,20]. Confalonieri and colleagues [6] showed, in
patients treated with hydrocortisone, a significant decrease in
the multiple organ dysfunction score (MODS) (from 1.2 on day
1 to 0.3 on day 8), whereas in the placebo group MODS
remained almost unchanged (from 1.2 to 1.0). Similarly, in the
hydrocortisone group, the authors found a significant
decrease in CRP, whereas in the placebo group CRP
increased even further from day 1 to day 8. Similar findings
were observed in gas exchange as demonstrated by the sig-
nificantly higher PaO2/FiO2 ratios of patients treated with
hydrocortisone on day 8 [6]. The correlation between organ
failure, assessed by MODS, and systemic inflammation,
assessed by CRP, suggests that a good clinical course is
associated with resolution of the inflammatory process
whereas a clinical deterioration is associated with ongoing
inflammation [33-35]. The exact mechanism of action of corti-
costeroids contributing to the observed effects is still
unknown; however, it is difficult to accept that it results prima-
rily from a direct effect on CRP concentration, decreasing
either its rate of synthesis or secretion. If that were the case,
patients on steroid therapy would have a blunted acute-phase
response with very low levels of CRP in response to an infec-
tion [36,37].Critical Care    Vol 12 No 3    Salluh et al.
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Conclusion
In a small prospective RCT and in a large retrospective cohort
study, treatment with systemic corticosteroids showed reduc-
tions in mortality or morbidity. However, the small sample sizes
[6,20,21], different treatment regimens [6,19-21], and non-
experimental design [19] of the studies reviewed may have
influenced the results significantly. Different selection criteria
may also have resulted in confounding by indication. The con-
cept of using corticosteroids for patients with severe CAP is
based on studies that should be categorized as both a weak
recommendation (two studies) and a strong recommendation
(two studies) with either low- or moderate-quality evidence,
thus reflecting a global 'weak recommendation'. Moreover, the
results are inconsistent and the mechanism that explains the
favorable results remains unclear. Therefore, given the current
evidence, it cannot be concluded that corticosteroids should
become part of the standard of care for patients admitted to
the hospital with severe CAP. However, despite the fact that
the rate of side effects from corticosteroids (myopathy, hyper-
glycemia, and nosocomial infections) was not systematically
investigated, all four studies failed to show worse outcomes
associated with the use of corticosteroids. Thus, it may be rea-
sonable to conclude that, in patients with COPD or asthma
receiving antimicrobial therapy, corticosteroid administration
may be considered safe. Particularly considering the recent
results of trials of corticosteroids in septic shock [27], future
RCTs should overcome the methodological flaws in the
designs of the currently available studies. To determine the
risks and benefits of adding corticosteroids to the treatment of
patients with severe CAP, large prospective randomized stud-
ies are necessary.
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